Acute Porphyria Drug Database

V03AB35 - Sugammadex
Propably not porphyrinogenic
PNP

Rationale
Sugammadex is not metabolized, but is excreted in unhanged form or as a complex.
Chemical description
Modified gamma cyclodextrin.
Therapeutic characteristics
Sugammadex is used for reversal of neuromuscular blockade induced by rocuronium or vecuronium. It is administered intravenously as a single bolus injection. It forms complexes by capsuling the neuromuscular blocking agents in plasma, thereby reducing the amounts available for binding to the nicotine receptor in the neuromuscular synapse.
Metabolism and pharmacokinetics
Sugammadex is not metabolized by the liver. Unchanged sugammadex or complex is excreted in the urine.

References

  1. Scientific articles
  2. Peeters P, Passier P, et al, Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Biopharm Drug Dispos. 2011 Apr;32(3):159-67. #3110
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Bridion. #3111

Similar drugs
Explore alternative drugs in similar therapeutic classes V03A / V03AB or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙